Literature DB >> 9413764

Zinc in the human prostate gland: normal, hyperplastic and cancerous.

T V Sviridova, S V Zaichick.   

Abstract

Zinc concentration in a prostate gland is much higher than in other human tissues. Data for zinc changes in different prostate diseases are limited and greatly contradictory. To analyze transrectal puncture tissue biopsy and resected materials, zinc content was estimated in benign prostatic hyperplasia (BPH) and cancer. There were 109 patients studied (50 BPH and 59 cancer). The control group consisted of 37 intact glands of men who died an unexpected death (accident, murder, acute cardiac insufficiency, etc.). All materials studied were divided into two parts. One of them was morphologically examined, while the zinc content of another one was estimated. The radionuclide induced energy dispersive X-ray fluorescent analysis was used for zinc determination. Zinc content (M +/- SE) of normal prostate, BPH and cancer was 1018 +/- 124, 1142 +/- 77, and 146 +/- 10 micrograms/g dry tissue, respectively. It was shown that zinc assessment in the material of transrectal puncture biopsy of prostate indurated site can be used as an additional test for differential diagnosis of BPH and cancer. Accuracy, sensitivity and specificity of the test are 98 +/- 2%.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9413764     DOI: 10.1007/bf02552202

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  19 in total

1.  Effect of zinc on androgen metabolism in the human hyperplastic prostate.

Authors:  A M Wallace; J K Grant
Journal:  Biochem Soc Trans       Date:  1975       Impact factor: 5.407

2.  THE CONCENTRATION OF ZINC IN DISEASED HUMAN PROSTATE GLANDS.

Authors:  G R SCHRODT; T HALL; W F WHITMORE
Journal:  Cancer       Date:  1964-12       Impact factor: 6.860

3.  The distribution of zinc within the human prostate.

Authors:  W K KERR; A G KERESTECI; H MAYOH
Journal:  Cancer       Date:  1960 May-Jun       Impact factor: 6.860

4.  Zinc plasma levels in prostatic carcinoma and BPH.

Authors:  M Lekili; A Ergen; I Celebi
Journal:  Int Urol Nephrol       Date:  1991       Impact factor: 2.370

5.  Zinc and magnesium in human prostate gland: normal, hyperplastic, and neoplastic.

Authors:  F Györkey; K W Min; J A Huff; P Györkey
Journal:  Cancer Res       Date:  1967-08       Impact factor: 12.701

6.  The concentration of zinc in relation to fundamental elements in the diseased human prostate.

Authors:  A Marczyńska; J Kulpa; J Leńko
Journal:  Int Urol Nephrol       Date:  1983       Impact factor: 2.370

7.  Zinc, cadmium and selenium concentrations in separated epithelium and stroma from prostatic tissues of different histology.

Authors:  A Feustel; R Wennrich; H Dittrich
Journal:  Urol Res       Date:  1987

8.  Metal-androgen interrelationships in carcinoma and hyperplasia of the human prostate.

Authors:  F K Habib; G L Hammond; I R Lee; J B Dawson; M K Mason; P H Smith; S R Stitch
Journal:  J Endocrinol       Date:  1976-10       Impact factor: 4.286

9.  Trace element profiles in cancer patients.

Authors:  W J Pories; A M van Rij; E G Mansour; A Flynn
Journal:  Biol Trace Elem Res       Date:  1979-08       Impact factor: 3.738

10.  Cancer of the prostate: early diagnosis by zinc and hormone analysis?

Authors:  F K Habib; M K Mason; P H Smith; S R Stitch
Journal:  Br J Cancer       Date:  1979-06       Impact factor: 7.640

View more
  68 in total

Review 1.  The intermediary metabolism of the prostate: a key to understanding the pathogenesis and progression of prostate malignancy.

Authors:  L C Costello; R B Franklin
Journal:  Oncology       Date:  2000-11       Impact factor: 2.935

Review 2.  Role of zinc in the pathogenesis and treatment of prostate cancer: critical issues to resolve.

Authors:  L C Costello; P Feng; B Milon; M Tan; R B Franklin
Journal:  Prostate Cancer Prostatic Dis       Date:  2004       Impact factor: 5.554

3.  Toenail trace element status and risk of Barrett's oesophagus and oesophageal adenocarcinoma: results from the FINBAR study.

Authors:  Michael A O'Rorke; Marie M Cantwell; Christian C Abnet; And John D Brockman; Liam J Murray
Journal:  Int J Cancer       Date:  2012-03-06       Impact factor: 7.396

Review 4.  Zinc in specialized secretory tissues: roles in the pancreas, prostate, and mammary gland.

Authors:  Shannon L Kelleher; Nicholas H McCormick; Vanessa Velasquez; Veronica Lopez
Journal:  Adv Nutr       Date:  2011-03-10       Impact factor: 8.701

5.  Evidence that Human Prostate Cancer is a ZIP1-Deficient Malignancy that could be Effectively Treated with a Zinc Ionophore (Clioquinol) Approach.

Authors:  Leslie C Costello; Renty B Franklin; Jing Zou; Michael J Naslund
Journal:  Chemotherapy (Los Angel)       Date:  2015-06

6.  Assessing prostate cancer growth with citrate measured by intact tissue proton magnetic resonance spectroscopy.

Authors:  R Dittrich; J Kurth; E A Decelle; E M DeFeo; M Taupitz; S Wu; C-L Wu; W S McDougal; L L Cheng
Journal:  Prostate Cancer Prostatic Dis       Date:  2012-01-31       Impact factor: 5.554

Review 7.  Zinc and zinc transporters in normal prostate and the pathogenesis of prostate cancer.

Authors:  Renty B Franklin; Beatrice Milon; Pei Feng; Leslie C Costello
Journal:  Front Biosci       Date:  2005-09-01

Review 8.  Mitochondrial function, zinc, and intermediary metabolism relationships in normal prostate and prostate cancer.

Authors:  L C Costello; R B Franklin; Pei Feng
Journal:  Mitochondrion       Date:  2005-06       Impact factor: 4.160

9.  Zinc intake from supplements and diet and prostate cancer.

Authors:  Alejandro Gonzalez; Ulrike Peters; Johanna W Lampe; Emily White
Journal:  Nutr Cancer       Date:  2009       Impact factor: 2.900

10.  High-dose dietary zinc promotes prostate intraepithelial neoplasia in a murine tumor induction model.

Authors:  Young Hwii Ko; Yu Jeong Woo; Jin Wook Kim; Hoon Choi; Seok Ho Kang; Jeong Gu Lee; Je Jong Kim; Hong Seok Park; Jun Cheon
Journal:  Asian J Androl       Date:  2009-12-14       Impact factor: 3.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.